Navigation Links
Toward understanding the dangers of the fake marijuana called 'Spice' or 'K2'
Date:10/2/2013

The harmful effects of increasingly popular designer cannabis products called "Spice" or "K2" have puzzled scientists for years, but now a group of researchers is reporting progress toward understanding what makes them so toxic. The study, published in the ACS journal Analytical Chemistry, describes development of a method that could someday help physicians diagnose and treat the thousands of young adults and teens who end up in emergency rooms after taking the drugs.

Jeffery Moran and colleagues note that synthetic marijuana, often marketed as "natural incense," "potpourri," Spice or K2, is a significant public health concern, and 1 in 9 high school seniors admit recent use. The products appear across the United States and Europe, and are the second most popular drug after real marijuana for many American teens and young adults. The substances produce a "high," but also can cause a wide range of dangerous side effects including seizures, hallucinations, severe kidney damage, psychotic behavior and heart attacks. Scientists are quickly playing catch-up to understand how these fake pot products work in order to identify them in users' urine and to treat the devastating health effects, which, in some cases, plague users for months after they initially take it.

To gain insight into the effects of designer marijuana products, Moran's team developed a new method and used it to study how the body processes two popular forms in Spice and K2, known as JWH-018 and AM2201. Urine samples from 15 people who tested positive for use showed significant differences in how the individuals' bodies processed the drugs. This finding could help explain why some people experience more severe effects from the drugs than others.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Insect-inspired super rubber moves toward practical uses in medicine
2. Toward a safer form of acetaminophen
3. New materials, progress toward an HIV vaccine, and more at meeting of crystallographers
4. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
5. Toward broad-spectrum antiviral drugs for common cold and other infections
6. NREL drives toward the future with fuel cell EVs
7. Engineered stem cell advance points toward treatment for ALS
8. A giant step toward miniaturization
9. The large-scale EU project EU BON: Towards integration with its global counterpart GEO BON
10. Towards more sustainable construction
11. Report: Water and Agriculture in Canada: Towards Sustainable Management of Water Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... , ... Parallel6™ , the leader in mClinical™ technologies for improving patient ... one of the 2017 Top 10 eClinical Trial Management Solution Providers by Pharma ... “We take pride in honoring Parallel6 as one of the top 10 companies that ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell ... cell technologies for neurodegenerative diseases, announced today that Chaim ... for Regenerative Medicine,s (ARM) 5 th Annual Cell & ... 09:40 EDT in Boston . ... Medical Officer & Chief Operating Officer, will participate in a ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of ... Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis ... clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of ...
Breaking Biology Technology: